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Abstract  
Background. Glutamine has been shown to improve the gut mucosal barrier. However, the 
evidence for benefit of enteral glutamine on intestinal permeability in acute pancreatitis (AP) is 
limited. 
Objective. To identify the effect of enteral glutamine supplementation on intestinal permeability in 
patients with AP. 
Method. A systematic search was conducted by extracting evidence from published studies on 
enteral glutamine supplementation in three databases (PubMed, Cochrane Central Register of 
Controlled Trials, and SciElo) relevant to AP from 1 January 2010 till 31 December 2020. Outcomes 
assessed were intestinal permeability, infectious complication, hospital length of stay, and 
mortality rate. 
Results. A total of 6 studies found by search, in which 2 human RCTs with 7 days duration of 
intervention with 1b-1c quality based on Criteria by Center of Evidence-Based Medicine, University 
of Oxford. Both studies showed the benefit of early enteral glutamine supplementation on 
intestinal permeability in patients with AP. 
Conclusions. Enteral glutamine supplementation has been shown to improve the gut mucosal 
barrier in AP. Despite its significant improvement in intestinal permeability, glutamine 
supplementation did not display a consistently positive effect on clinical outcomes. 




AP: acute pancreatitis  
EN: enteral nutrition  
LMR: lactulose mannitol ratio  
LOS: length of stay  
SAP: severe acute pancreatitis  










Acute pancreatitis (AP) is one of the most common 
causes of hospitalization for a gastrointestinal 
condition in the United States, with a global 
incidence ranging from 5–30 cases per 100,000 
population per year.1 In the Eastern countries, 
especially Asia, the most common cause of AP is 
biliary disease (49–54%) followed by alcohol abuse 
(20%).2 AP is an acute, non-bacterial inflammation 
of the pancreas, in which auto digestion of activated 
pancreatic enzymes occurs and results in edema, 
vascular damage, bleeding, and necrosis of the 
pancreas.3 Approximately 20% of patients develop 
severe acute pancreatitis (SAP) with a substantial 
mortality rate of 20–40% in the presence of 
Corresponding author: 
Evania Astella Setiawan 
Department of Nutrition, Faculty of Medicine, Universitas 
Indonesia 
Jl. Salemba Raya no.6, Central Jakarta, Indonesia 
Email: evania.astella@gmail.com 
 
World.Nutr.Journal | 47  
pancreatic necrosis.4 In SAP, inflammatory response 
causes disruption of the intestinal barrier and 
translocation of gram-negative bacteria which can 
be responsible for infection of the necrotic pancreas, 
systemic inflammatory response (SIRS), sepsis, and 
multi organ dysfunction syndrome (MODS). Hence, 
the main goals of treatment in SAP is to maintain the 
integrity of the gut barrier since the early phase 
focusing attention on the role of gut as the first 
course for SAP systemic complications.3,5 
Originally, patients with SAP were made nil per 
os (NPO) to minimize stimulation of the pancreas 
and to reduce pain. Despite the NPO state, patients 
were given total parenteral nutrition (TPN).6 Lack of 
enteral feeding in TPN results in gastrointestinal 
mucosal atrophy, bacterial overgrowth, increased 
intestinal permeability and translocation of bacteria, 
which contribute to poorer prognosis.7 In contrary, 
meta-analysis by Petrov, et al.8 showed that enteral 
nutrition (EN) results in significant risk reduction 
for morbidity and mortality in patients with 
predicted SAP. Moreover, systematic review by 
McClave, et al.9 also suggested that patients with 
SAP should begin EN early as it allows a trophic 
action on the intestinal wall, which maintain the 
intestinal barrier and prevent the bacterial 
translocation and results in better outcome.6 Recent 
meta-analysis by Zhou, et al.10 showed beneficial 
effect of adding immune-enhanced formulas to the 
standard nutrition therapy in patients with AP either 
via the enteral or parenteral route. Glutamine, as one 
of the immunonutrition, which is also the major 
substrate for intestinal cells, have been investigated 
for its protective effects on intestinal mucosal 
integrity and modulation of inflammatory 
response.11,12 Several meta-analysis have been 
performed assessing the effects of parenteral and 
enteral administration of glutamine compared with 
conventional methods.10,13,14 Studies confirm the 
improvements in serum albumin, C-reactive protein 
(CRP),13,14 incidence of infection and mortality rate. 
10,13,14 To our knowledge, there are no review yet 
discussing the effects of enteral administration of 
glutamine on intestinal integrity. This review will 
investigate the role of enteral glutamine 
supplementation on intestinal integrity in acute 
pancreatitis, along with mortality and morbidity in 
terms of infectious complication and hospital length 
of stay (LOS). 
Clinical question 
 
A 30-year-old woman was admitted to the hospital 
with 24h severe epigastric pain and intractable 
vomiting. Two days before admission, the patient 
began to have fever, headache, and nausea. The pain 
was worsened with eating. Her past medical history 
was otherwise negative, and she had no allergies. 
She denied alcohol intake or tobacco use. She has a 
two-time history of cesarean section, which was last 
two years ago. Examination revealed a woman with 
38.5˚C fever and epigastric abdominal pain during 
superficial palpation, with no peritonitis signs. There 
were non-palpable masses and bowel sounds were 
normal. Abdominal ultrasonography showed a 
contracted gallbladder without lithiasis with normal 
biliary tree, hypoechoic extrapancreatic 
inflammation and pancreatic parenchymal 
inhomogeneity, with small amount of fluid localized 
peri-hepatic and in rectouterine pouch. Laboratory 
investigations showed leucocytosis, elevated serum 
lipase (3212 U/L) and amylase (278 U/L), and 
elevated IgM/IgG EndoCab. The patient was 
diagnosed with acute pancreatitis and immediately 
placed on a nasogastric tube and started to be given 
EN within 24 hours. The physician in charge would 
provide early enteral nutrition and investigate 
whether enteral glutamine has a role to improve 
intestinal permeability and subsequently reduce 




Three electronic bibliographic databases (Pubmed, 
Cochrane Central Register of Controlled Trials, and 
SciElo) were systematically searched by author 
E.A.S. All randomized controlled trials (RCTs) of 
enteral glutamine supplementation in acute 
pancreatitis between January 1, 2010 and December 
31, 2020 were included in this review. Any included 
study had to assess intestinal integrity as an outcome 
and had to be a human trial in adults. We used the 
search terms 'glutamine' AND ('enteral' OR ‘oral’) 
AND ('pancreatitis' OR ‘acute pancreatitis’) AND 
(‘intestinal permeability’ OR ‘gut permeability’) to 
identify relevant studies (Table 1). Publications in 
non-English languages, unpublished studies, online 
proceeding, and non-full text paper were not 
included. 
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Titles and abstracts were screened by author E.A.S 
to identify relevant studies. Full-text articles of 
potentially eligible studies that met the selection 
criteria were obtained. The inclusion criteria for this 
review were RCT, participants aged at least 18 years 
old, single glutamine intervention, enteral 
administered intervention, and intestinal 
permeability as main outcome. Non-RCT, 
participants aged under 18 years old, and review 
articles were excluded. Any discrepancy was 
discussed with the senior author D.S.  
All data from the eligible studies were extracted 
into tabular form. Extracted data included 
information on the first author, the country where 
the trial was held, the study population and sample 
size, intervention and comparison groups, the 
duration of intervention, the outcomes measured and 
their time of assessment, and the results of the 
clinical and/or laboratory parameter outcomes. The 
quality of the studies was assessed by two authors 
(E.A.S., D.S.) using guideline for RCT based on 
Criteria by Center of Evidence-Based Medicine, 
University of Oxford and the summary is provided 
in Table 2. Outcome measurements included 
intestinal integrity, incidence of infectious 




The study selection process is summarized in Figure 
1. The initial systematic search identified 6 citations 
of which 2 potentially eligible articles15,16 was 
critically appraised. We excluded 4 study for 
duplications and non-human study. One record from 
PubMed excluded was a non-human study and three 
records from Cochrane were excluded for 
duplication. Details of the included studies are 
presented in Table 3 and Table 4. Two studies 
included in this review were RCTs of enteral 
glutamine supplementation in acute pancreatitis for 
7 days which investigated intestinal permeability as 
an outcome.15,16 Biomarkers used to assess intestinal 
permeability were different in both studies. Other 
outcomes included in this review were incidence of 







Study by Arutla M, et al.15 showed significant 
reduction of polyethylene-glycol (PEG) in the 
intervention group after 7 days of supplementation. 
PEG, as well as sugars, or 51chromium-labelled 
ethylenediamine tetra-acetic acid (51CrEDTA) are 
probes used for examining intestinal permeability. 
Intestinal permeability analysis is based on the 
appearance of orally administered probes in the 
circulation and/or urine after permeation of the 
intestinal epithelium. Each probe has its specific 
advantages and disadvantages and requires a 
specific method of detection. PEG is one of the 
commonly used option for permeability analysis 
which is based on the use of PEG probes. PEG has 
few advantages over the use of 51CrEDTA and 
sugars for permeability analysis, such as it does not 
require radioactivity, it is not metabolized by 
enzymes or degraded by bacteria within the human 
gastrointestinal tract, and it is analyzed using less 
expensive and time-consuming method than other 
probes.17 High levels of PEG found in the circulation 
indicates increased intestinal permeability. 
Significant reduction of PEG after enteral glutamine 
supplementation in AP demonstrate the beneficial 
effect of glutamine on intestinal permeability. 
Glutamine is essential for the growth, survival, 
and physiological health of actively dividing cells 
such as enterocytes, fibroblasts, and lymphocytes. 
Gastrointestinal mucosal integrity is quickly 
restored and maintained by cell proliferation, 
migration, and differentiation. Enteral feeding 
appears to be the primary stimulus for the regulation 
of proliferative response in the intestinal tract, which 
is accomplished mainly by the glutamine. Gut 
mucosa is the major site of glutamine metabolism in 
which glutamine is a major source of energy for 
proliferation and differentiation of intestinal 
epithelial cells. Under conditions of severe 
inflammation, the physiological level of glutamine 
is inadequate to balance the damage and needs to be 
replaced.18 Not only act as fuel for enterocyte, 
glutamine also modulates the inflammatory 
response and oxidative reactions, in which 
ultimately maintain the tight junction of intestinal 
cells.19 
It has been identified that glutamine 
administration influences intestinal permeability. 
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However, which route is the most appropriate in 
providing glutamine supplementation to benefit gut 
integrity is still debatable. Enteral and parenteral 
glutamine supplementations have different 
metabolic pathways. A pilot study by Uranjek, et 
al.20 investigating the effect of the route of glutamine 
supplementation on intestinal permeability in 81 
intensive care unit (ICU) patients. The study showed 
no significant difference in lactulose mannitol ratio 
(LMR) between enteral glutamine compared with 
parenteral route. 
Ligthart-Melis, et al.21 demonstrated their study 
in 16 patients undergoing upper gastrointestinal 
surgery to receive an IV or EN infusion of L-[2-
(15)N]glutamine. The study revealed that arterial 
[(15)N] glutamine was significantly lower during 
EN reflecting intestinal metabolism preferably takes 
up enterally administered glutamine compared with 
intravenously provided glutamine. This suggests 
that the route of administration of glutamine 
supplementation is influenced by the underlying 
condition. 
The second study included in this review was 
study by Singh, et al.16 which evaluating the effect 
of oral glutamine supplementation on gut 
permeability and endotoxemia (surrogate end point) 
in patients with SAP. The study discovered there 
was no significant difference in LMR between 
intervention and control group after intervention. 
However, there was significant increase in IgM 
antiendotoxin antibodies in intervention group. 
Similar to study by Sharma, et al.22 investigating 
the intestinal permeability and anti-endotoxin 
antibodies immunoglobulin in SAP compared to 
healthy controls. The study showed that the 
intestinal permeability (LMR) at day 1 and day 7 of 
admission was no different when compared with 
controls. In the natural course of AP, intestinal 
permeability has been found to increase gradually 
within the first 72 hours and normalize slowly from 
the second week to one and a half months.23-25 
Singh, et al.16 also demonstrated insignificant 
changes in LMR after glutamine supplementation in 
the intervention group as well as control group, 
possibly because of the maintained gut mucosal 
barrier of patients that were fed enterally. The IgM 
endotoxin antibody titer is an indirect marker for 
endotoxemia. The study found a significant increase 
in IgM endotoxin antibody in the group receiving 
glutamine after 7 days of intervention suggesting the 
decreased of endotoxemia. Compared to other 
studies with non-conclusive results, Pearce, et al.26 
conducted a study on 31 AP patients given enteral 
feed containing glutamine, arginine, and omega-3 
fatty acid compared to isonitrogenous & isocaloric 
enteral feed for 3 days. There was significant 
difference in increment of IgG antiendotoxin 
antibody in control group compared to intervention 
group, however this effect was not seen in the IgM 
antiendotoxin antibodies and the explanation for this 
effect is not entirely clear. 
Even though there was significant increase in 
intestinal permeability with enteral glutamine 
administration, both studies did not show a 
consistent clinical improvement as evidenced by 
equal infectious complications, hospital stay, or 
mortality in both groups. In line with meta-analysis 
investigating clinical benefit of immunonutrition 
over standard enteral formulas in patients with acute 
pancreatitis. There is no evidence that enteral 
nutrition supplemented with glutamine, arginine 
and/or omega-3 fatty acids has beneficial effect on 
infectious complications, hospital LOS, and 
mortality rate in acute pancreatitis compared to 
standard EN.8 
Both included studies reported significant 
improvement in intestinal permeability. These 
studies were conducted in the same country. India, 
like any other developing countries, is concerned 
with spectrum of enteropathies, characterized by 
small intestinal inflammation, reduced absorptive 
capacity, and increased intestinal permeability.27 
This condition commonly affect people in 
developing countries as Menzies, et al.28 speculated 
that in many tropical countries, especially where 
there is widespread poverty and poor sanitation, may 
be exposed to repeated gastrointestinal infection 
leading to a chronic reversible impairment of 
intestinal function. 
Studies included in this review demonstrated 
beneficial effects of enteral glutamine 
supplementation on intestinal permeability in acute 
pancreatitis. However, this beneficial effect did not 
in accordance with any clinical improvements, for 
instance incidence of infectious complications, 
hospital LOS, and mortality rate. Despite significant 
improvement in intestinal permeability, both studies 
were underpowered consequently the results 
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obtained with enteral glutamine cannot be advocated 
for routine administration in patients with AP. An 
adequately powered larger study with longer 
duration of supplementation is required to 




The goal of nutritional support in AP is to reduce 
inflammation and maintain intestinal permeability. 
Enteral glutamine supplementation has been shown 
to improve gut mucosal barrier in AP. Despite its 
significant improvement in intestinal permeability, 
glutamine supplementation did not display a 
consistent positive effect on clinical outcome. 
 
What is Already Known 
Acute pancreatitis (AP) is associated with altered 
gut mucosal barrier. 
Glutamine supplementation have been shown to 
improve gut mucosal barrier in AP. 
 
What This Study Adds 
Enteral glutamine supplementation improves 
intestinal permeability in AP patients 
 
What are the future clinical and research 
implications of the study findings? 
Investigators need to evaluate the effects of long-
term enteral glutamine supplementation in a large 









































Table 1. Terminology used in three databases 
 
Database Terminology Hits Result 
PubMed (((((glutamine[Title/Abstract]) OR (glutamine[MeSH Terms])) AND 
((((enteral[Title/Abstract]) OR (enteral[MeSH Terms]) OR 
(oral[Title/Abstract]) OR (oral[MeSH Terms])))) AND 
((((pancreatitis[Title/Abstract]) OR (pancreatitis[MeSH Terms]) OR (acute 
pancreatitis[Title/Abstract]) OR (acute pancreatitis[MeSH Terms])))) AND 
((((intestinal permeability[Title/Abstract]) OR (intestinal permeability[MeSH 
Terms]) OR (gut permeability[Title/Abstract]) OR (gut permeability[MeSH 
Terms])))) 





(glutamine):ti,ab,kw AND ("Enteral"):ti,ab,kw AND (pancreatitis):ti,ab,kw 
AND ("intestinal permeability"):ti,ab,kw 
Filter: published in the last 10 years 
3 0 
SciElo (glutamine) AND (enteral) AND (pancreatitis) AND (intestinal permeability) 
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Table 2. Critical appraisal of the RCT study based on criteria by Center of Evidence-Based Medicine, University 
of Oxford 
 
Parameters Questions Arutla M, et al.15 Singh N, et al.16 
Validity Was the assignment of patient to treatments 
randomized? 
Yes Yes 
 Was the randomization list concealed? No Yes 
 Were the groups similar at the start of the trial? Yes Yes 
 Aside from the allocated treatment, were groups 
treated equally? 
No Yes 
 Were all patients who entered the trial accounted 
for? 
Yes Yes 
 Were they analyzed in the group to which they 
were randomized? 
Yes Yes 
 Were measures objective or were the patients and 
clinicians kept “blind” to which treatment was 
being received? 
No Yes 
Importance How large was the treatment effect? Polyethylene glycol 
reduction in 
intervention group (7.61 
± 4.5), P = 0.02 
IgM antiendotoxin Ab 
increment in 
intervention group (P = 
0.0164) 
 How precise was the estimate of the treatment 
effect? 
Precise, the 95% CI of 
the results are narrow. 
Poly-ethylene glycol 
reduction in 
intervention group (7.61 
± 4.5), P = 0.02 
Precise, the 95% CI of 
the results are 
narrow. 
Applicability Is my patient so different to those in the study that 
the results cannot apply? 
Precise, the 95% CI of 
the results are narrow. 
The study has the same 
characteristic as case 
scenario 
The study has the same 
characteristic as case 
scenario 
 Is the treatment feasible in my setting? No No 
 Will the potential benefit of treatment outweigh the 
potential harms of treatment for my patient? 
Yes Yes 
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Table 3. Characteristic of the included studies assessing the effect of enteral glutamine supplementation on 





















18-60 years old 
with AP with ≤ 
72 hours of the 
onset of 
abdominal pain 
+ APACHE II 
score ≥ 8 or 
SOFA score ≥ 2 
or SIRS > 2 for 
48 h or BUN 
rise > 5 mg/dL 









≤ 48 hours 
of admission 










18-80 years old 
with acute 
pancreatitis 





10 g glutamine 
(KABIMMUNE) 
twice a day 
 
10 g whey 
protein 
twice a day 
≤ 7 days of 
the onset of 
symptom 
7 days 20 g/day 
AP, acute pancreatitis; APACHE, acute physiology and chronic health evaluation; BUN, blood urea nitrogen; C, control group; I, intervention 
group; SIRS, systemic inflammatory response syndrome; SOFA, sequential organ failure assessment
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Intestinal permeability Complication of 
infection 








There was significant PEG 
reduction in I group. 
 
Group I 
Day 1 (n 18/18): 39.91 ± 11.9 
Day 7 (n 18/18): 32.30 ± 7.4 
P = 0.02 
 
Group C 
Day 1 (n 22/22): 48.73 ± 12.6 
Day 7 (n 22/22): 45.25 ± 7.9 
P = 0.32 











P = 0.53 




between I and C 
group. 
 
I: 15.58 ± 10.3 
days 
C: 15.63 ± 18.8 
days 
P = 0.99 
There was no 
difference in in-
hospital mortality 




C: 1/22  








There was no significant 
difference in LMR between I 
and C group after 
intervention. 
Group I 
Day 7 (n 29/41): 0.15 (0.02-2) 
Group C 
Day 7 (n 28/39): 0.14 (0.01-5) 
P = 0.8732 
 
There was no significant 
increase in IgG antiendotoxin 
antibody in both I and C 
group. 
Group I 
Day 0 (n 39/41): 72 (4-1600) 
Day 7 (n 36/41): 86 (4-1600) 
P = 0.1667 
 
Group C 
Day 0 (n 35/39): 74 (4-1760) 
Day 7 (n 29/39): 100 (2-1640) 
P = 0.7293 
 
There was significant increase 
in IgM antiendotoxin 
antibody in I group. 
Group I 
Day 0 (n 41/41): 33 (4-175) 
Day 7 (n 37/41): 40 (8-350) 
P = 0.0164 
Group C 
Day 0 (n 38/39): 45 (2-180) 
Day 7 (n 32/39): 56 (7-350) 
P = 0.1552 
There was no 
difference in 
complication of 
infection between I 




P = 1.000 




between I and C 
group. 
 
I: 12 (1-101) days 
C: 11 (2-36) days 
P = 0.236 
There was no 
difference in in-
hospital mortality 
between I and C 
group. 
 
I: 5/41  
C: 6/39  
P = 0.753 







World.Nutr.Journal | 55  
Conflict of Interest 
 





This article is distributed under the terms of the  
Creative Commons Attribution 4.0 International 
Licence 
(http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons 
license, and indicate if changes were made. 
 
References 
1. Siregar GA and Siregar GP. Management of severe 
acute pancreatitis. Maced J Med Sci. 2019;7:3319-
3323. 
2. Derrick D, Frandy F, Wirawan AD. Acute pancreatitis – 
etiology, pathogenesis, pathophysiology and the current 
trend in its management and prevention. The 
Indonesian Journal of Gastroenterology, Hepatology 
and Digestive Endoscopy. 2019;20:27-37. 
3. Li XY, He C, Zhu Y, Lu NH. Role of gut microbiota on 
intestinal barrier function in acute pancreatitis. World J 
Gastroenterol. 2020;26:2187-2193. 
4. Boxhoorn L, Voermans RP, Bouwense SA, Bruno MJ, 
Verdonk RC, Boermeester MA, et al. Acute pancreatitis. 
Lancet. 2020;396:726–34. 
5. Capurso G, Zerboni G, Signoretti M, Valente R, 
Stigliano S, Piciucchi M, et al. Role of the gut barrier in 
acute pancreatitis. J Clin Gastroenterol. 2012;46:S46–
S51. 
6. Roberts KM, Nahikian-Nelms M, Ukleja A, Lara LF. 
Nutritional aspects of acute pancreatitis. Gastroenterol 
Clin N Am. 2017. 
7. Marik PE. What is the best way to feed patients with 
pancreatitis? Curr Opin Crit Care. 2009;15:131–138. 
8. Petrov MS, van Santvoort HC, Besselink MGH, van der 
Heijden GJMG, Windsor JA, Gooszen HG. Enteral 
nutrition and the risk of mortality and infectious 
complications in patients with severe acute pancreatitis: 
a meta-analysis of randomized trials. Arch Surg. 
2008;143:1111-1117. 
9. McClave SA, Chang WK, Dhaliwal R, Heyland DK. 
Nutrition support in acute pancreatitis: a systematic 
review of the literature. JPEN J. Parenter. Enteral Nutr. 
2006;30:143–156. 
10. Zhou J, Xue Y, Liu Y, Li X, Tong Z, Li W. The effect of 
immunonutrition in patients with acute pancreatitis: a 
systematic review and meta-analysis. J Hum Nutr Diet. 
2020. 
11. Kim MH and Kim HY. The roles of glutamine in the 
intestine and its implication in intestinal diseases. Int J 
Mol Sci. 2017;18:1051-1066. 
12. Perna S, Alalwan TA, Alaali Z, Alnashaba T, Gasparri 
C, Infantino V, et al. The role of glutamine in the 
complex interaction between gut microbiota and health: 
a narrative review. Int J Mol Sci. 2019;20:5232-5243. 
13. Yong L, Lu QP, Liu SH, Fan H. Efficacy of glutamine-
enriched nutrition support for patients with severe acute 
pancreatitis: a meta-analysis. JPEN J. Parenter. Enteral 
Nutr. 2015. 
14. Jiang X, Pei LY, Guo WX, Qi X, Lu XG. Glutamine 
supported early enteral therapy for severe acute 
pancreatitis: A systematic review and metaanalysis. 
Asia Pac J Clin Nutr 2020;29(2):253-261 
15. Arutla M, Raghunath M, Deepika G, Jakkampudi A, 
Murthy HVV, Rao GV, et al. Efficacy of enteral 
glutamine supplementation in patients with severe and 
predicted severe acute pancreatitis—A randomized 
controlled trial. Indian J Gastroenterol. 2019. 
16. Singh N, Mishra SK, Sachdev V, Sharma H, Upadhyay 
AD, Arora I, et al. Effect of oral glutamine 
supplementation on gut permeability and endotoxemia 
in patients with severe acute pancreatitis: a randomized 
controlled trial. Pancreas. 2014;43:867-873. 
17. Wijck KV, Bessems BAFM, Eijk HMHV, Buurman 
WA, Dejong CHC, Lenaerts K. Polyethylene glycol 
versus dual sugar assay for gastrointestinal permeability 
analysis: is it time to choose? Clinical and Experimental 
Gastroenterology. 2012:5;139–150. 
18. Rao RK and Samak G. Role of Glutamine in Protection 
of Intestinal Epithelial Tight Junctions. J Epithel Biol 
Pharmacol. 2012;5:47–54. 
19. Achamrah N, De´chelotte P, Coeffier M. Glutamine and 
the regulation of intestinal permeability: from bench to 
bedside. Curr Opin Clin Nutr Metab Care. 2017;20:86–
91. 
20. Uranjek J, Vovk I, Kompan L. Effect of the route of 
glutamine supplementation (enteral versus parenteral) 
on intestinal permeability on surgical intensive care unit 
patients: A pilot study. Surgical Practice. 2013;17:153–
160. 
21. Ligthart-Melis GC, Van de Poll MC, Dejong CH, 
Boelens PG, Deutz NE, Van Leeuwen PA. The route of 
administration (enteral or parenteral) affects the 
conversion of isotopically labelled L – [2-15N] 
glutamine into citrulline and arginine in humans. JPEN 
J. Parenter. Enteral Nutr. 2007;31:343–50. 
22. Sharma M, Sachdev V, Singh N, Bhardwaj P, Pal A, 
Kapur S, et al. Alterations in intestinal permeability and 
endotoxemia in severe acute pancreatitis. Tropical 
Gastroenterology. 2012;33:45–50. 
23. Ammori BJ, Leeder PC, King RF. Early increase in 
intestinal permeability in patients with severe acute 
pancreatitis: correlation with endotoxemia, organ 
failure and mortality. J Gastrointest Surg. 
1998;2:518Y525. 
24. Nagpal K, Minocha VR, Agrawal V, Kapur S. 
Evaluation of intestinal mucosal permeability function 
 
World.Nutr.Journal | 56  
in patients with acute pancreatitis. Am J Surg. 
2006;192:24–8. 
25. Juvonen PK, Alhava EM, Takala JA. Gut permeability 
in patients with acute pancreatitis. Scand J 
Gastroenterol. 2000;35:1314–8. 
26. Pearce CB, Sadek SA, Walters AM, Goggin PM, 
Somers SS, Toh SK, et al. A double-blind, randomised, 
controlled trial to study the effects of an enteral feed 
supplemented with glutamine, arginine, and omega-3 
fatty acid in predicted acute severe pancreatitis. J 
Pancreas (Online). 2006;7:361-371. 
27. Prendergast A and Kelly P. Review: enteropathies in the 
developing world: neglected effects on global health. 
Am J Trop Med Hyg. 2012;86:756–763. 
28. Menzies IS, Zuckerman MJ, Nukajam WS, 
Somasundaram SG, Murphy B, Jenkins AP, et al. 
Geography of intestinal permeability and absorption. 
Gut. 1999;44:483–489. 
 
